Literature DB >> 17545720

The toll-like receptor 4 Asp299Gly variant and tuberculosis susceptibility in HIV-infected patients in Tanzania.

Bart Ferwerda1, Gibson S Kibiki, Mihai G Netea, Wil M V Dolmans, Andre J van der Ven.   

Abstract

Toll-like receptor 4 (TLR4) plays an important role in the pattern recognition of Mycobacterium tuberculosis, and polymorphisms in the TLR4 gene influence the function of the receptor. We therefore investigated in a cohort of HIV-infected Tanzanian patients whether the Asp299Gly TLR4 polymorphism is associated with the development of active tuberculosis. We found a greater risk of developing active tuberculosis as well as a reduction in CD4 T-cell counts in patients with the Asp299Gly TLR4 polymorphism.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17545720     DOI： 10.1097/QAD.0b013e32814e6b2d

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  22 in total

Review 1.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

2.  Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis.

Authors:  Javeed A Shah; Jay C Vary; Tran T H Chau; Nguyen D Bang; Nguyen T B Yen; Jeremy J Farrar; Sarah J Dunstan; Thomas R Hawn
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

Review 3.  Toll-like receptor signaling in primary immune deficiencies.

Authors:  Paul J Maglione; Noa Simchoni; Charlotte Cunningham-Rundles
Journal:  Ann N Y Acad Sci       Date:  2015-04-30       Impact factor: 5.691

Review 4.  Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases.

Authors:  C Skevaki; M Pararas; K Kostelidou; A Tsakris; J G Routsias
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  R753Q polymorphism inhibits Toll-like receptor (TLR) 2 tyrosine phosphorylation, dimerization with TLR6, and recruitment of myeloid differentiation primary response protein 88.

Authors:  Yanbao Xiong; Chang Song; Greg A Snyder; Eric J Sundberg; Andrei E Medvedev
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

6.  The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF.

Authors:  Leandra Figueroa; Yanbao Xiong; Chang Song; Wenji Piao; Stefanie N Vogel; Andrei E Medvedev
Journal:  J Immunol       Date:  2012-04-02       Impact factor: 5.422

7.  Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis.

Authors:  Theo S Plantinga; Omar J M Hamza; Janet A Willment; Bart Ferwerda; Nicole M D van de Geer; Paul E Verweij; Mecky I N Matee; Kathy Banahan; Luke A J O'neill; Bart-Jan Kullberg; Gordon D Brown; André J A M van der Ven; Mihai G Netea
Journal:  J Acquir Immune Defic Syndr       Date:  2010-09       Impact factor: 3.731

8.  TLR4, IL10RA, and NOD2 mutation in paediatric Crohn's disease patients: an association with Mycobacterium avium subspecies paratuberculosis and TLR4 and IL10RA expression.

Authors:  Josef Wagner; Narelle A Skinner; Anthony G Catto-Smith; Donald J S Cameron; Wojtek P Michalski; Kumar Visvanathan; Carl D Kirkwood
Journal:  Med Microbiol Immunol       Date:  2013-03-02       Impact factor: 3.402

9.  Toll-like receptor 9 polymorphisms influence mother-to-child transmission of human immunodeficiency virus type 1.

Authors:  Elisabetta Ricci; Sandro Malacrida; Marisa Zanchetta; Ilaria Mosconi; Marco Montagna; Carlo Giaquinto; Anita De Rossi
Journal:  J Transl Med       Date:  2010-05-25       Impact factor: 5.531

Review 10.  Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.

Authors:  Andrei E Medvedev
Journal:  J Interferon Cytokine Res       Date:  2013-05-15       Impact factor: 2.607
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.